IR@PKUHSC  > 北京大学临床肿瘤学院  > 流行病学研究室
学科主题临床医学
Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention
Feng, Guo-Shuang1; Ma, Jun-Ling1; Wong, Benjamin C. Y.2; Zhang, Lian1; Liu, Wei-Dong5; Pan, Kai-Feng1; Shen, Lin3; Zhang, Xiao-Dong3; Li, Jie3; Xia, Harry H. X.2; Li, Ji-You4; Lam, Shiu Kum2; You, Wei-Cheng1
关键词Celecoxib Gastroduodenal Ulcer Cardiovascular Diseases Adverse Effects Epidemiology Randomized Controlled Trial
刊名WORLD JOURNAL OF GASTROENTEROLOGY
2008-07-28
DOI10.3748/wjg.14.4535
14期:28页:4535-4539
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Gastroenterology & Hepatology
研究领域[WOS]Gastroenterology & Hepatology
关键词[WOS]RHEUMATOID-ARTHRITIS ; COX-2 INHIBITORS ; GASTROINTESTINAL TOXICITY ; RISK ; ROFECOXIB ; CYCLOOXYGENASE-2 ; OSTEOARTHRITIS ; NSAIDS ; POPULATION ; DICLOFENAC
英文摘要

AIM: To evaluate the long-term risk of gastroduodenal ulcer and cardiovascular events induced by celecoxib in a population-based, randomized, double-blind, placebo-controlled study.

METHODS: From 2004 to 2006, a total of 1024 Chinese patients (aged 35 to 64 years) with severe chronic atrophic gastritis, intestinal metaplasia or dysplasia were randomly assigned to receive 200 mg of celecoxib twice daily or placebo in Linqu County (Shandong Province, China), a high-risk area of gastric cancer. All gastroduodenal ulcer and cardiovascular events occurred were recorded and the patients were followed up for 1.5 years after treatment. At the end of the trial, a systematic interview survey about other adverse events was conducted.

RESULTS: Gastroduodenal ulcer was detected in 19 of 463 (3.72%) patients who received celecoxib and 17 of 473 (3.31%) patients who received placebo, respectively (odds ratio = 1.13, 95% CI = 0.58-2.19). Cardiovascular (CV) events occurred in 4 patients who received celecoxib and in 5 patients who received placebo, respectively. Compared with those who received placebo, patients who received celecoxib had no significant increase in occurrence of CV events (hazard ratio = 0.84, 95% CI = 0.23-3.15). Among the adverse events acquired by interview survey, only the frequency of bloating was significantly higher in patients treated with celecoxib than in those treated with placebo.

CONCLUSION: Treatment of gastric cancer with celecoxib is not associated with increased risk of gastroduodenal ulcer and cardiovascular events. (C) 2008 The WJG Press. All rights reserved.

语种英语
WOS记录号WOS:000258263500017
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52612
专题北京大学临床肿瘤学院_流行病学研究室
作者单位1.Healthy Bur Linqu Cty, Weifang 262600, Shandong, Peoples R China
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Canc Epidemiol, Beijing 100036, Peoples R China
3.Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Med Oncol, Beijing 100036, Peoples R China
5.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Pathol, Beijing 100036, Peoples R China
推荐引用方式
GB/T 7714
Feng, Guo-Shuang,Ma, Jun-Ling,Wong, Benjamin C. Y.,et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2008,14(28):4535-4539.
APA Feng, Guo-Shuang.,Ma, Jun-Ling.,Wong, Benjamin C. Y..,Zhang, Lian.,Liu, Wei-Dong.,...&You, Wei-Cheng.(2008).Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention.WORLD JOURNAL OF GASTROENTEROLOGY,14(28),4535-4539.
MLA Feng, Guo-Shuang,et al."Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention".WORLD JOURNAL OF GASTROENTEROLOGY 14.28(2008):4535-4539.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Feng, Guo-Shuang]的文章
[Ma, Jun-Ling]的文章
[Wong, Benjamin C. Y.]的文章
百度学术
百度学术中相似的文章
[Feng, Guo-Shuang]的文章
[Ma, Jun-Ling]的文章
[Wong, Benjamin C. Y.]的文章
必应学术
必应学术中相似的文章
[Feng, Guo-Shuang]的文章
[Ma, Jun-Ling]的文章
[Wong, Benjamin C. Y.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。